Daxor Launches New BVA Program at High-Volume Ohio Cardiology Center, Boosting Customer Footprint
DXR sits 25% above its 52-week low of $7.1.
Summary
Daxor Corporation announced the launch of a new Blood Volume Analysis (BVA) program at a high-volume cardiology facility in Southwest Ohio. This strategic expansion leverages Daxor's ezBVA Lab workflow, providing the center with 24-hour turnaround on blood volume metrics without requiring onsite lab infrastructure. For a company of Daxor's size, securing a new program at a significant medical center represents a material step in commercial adoption and revenue growth for its diagnostic technology. This follows recent news of clinical data validation, indicating a positive progression from clinical evidence to market penetration. This move is expected to improve patient outcomes and reduce healthcare costs by enabling data-driven clinical decisions.
At the time of this announcement, DXR was trading at $8.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.7M. The 52-week trading range was $7.10 to $14.76. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.